ContextVision launches two breast cancer diagnostic imaging solutions at ECR 2011

ContextVision, the software imaging partner for the most recognized medical imaging manufacturers worldwide, today introduced two innovative solutions at the 2011 European Congress of Radiology (ECR). A mammography solution addresses current limitations of x-ray image diagnosis for the detection of breast cancer, while the interventional radiology solution helps achieve superior, real-time images with the ability for dose reduction during interventional fluoroscopy procedures.

“We are thrilled to launch our newest product innovations, the MAMMO PlusViewCAD and the GOPView iRVUltra, to a prestigious audience of radiology professionals and medical imaging equipment manufacturers”

Routine mammographic screening is an accepted standard for the early detection of breast cancer. However, as many as 1 in 5 cancers are overlooked by the radiologist because the signs on the mammogram may be extremely subtle. With the help of CAD systems, the mammographic image is used to evaluate a patient with abnormal clinical findings and alert the radiologist to the need for further analysis. A study published in the American Journal of Roentgenology found that the use of CAD systems significantly improved the detection of breast cancer by increasing radiologist sensitivity by 21.2%. In conclusion, for every 100,000 women with breast cancer identified without the use of computer-aided detection, an estimated additional 21,200 cancers would be found with the use of computer-aided detection.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover key genes linked to DCIS progression